Last reviewed · How we verify

Latanoprost/Timolol

Universiti Kebangsaan Malaysia Medical Centre · FDA-approved active Small molecule

Latanoprost/Timolol is a Prostaglandin analog / Beta-blocker combination Small molecule drug developed by Universiti Kebangsaan Malaysia Medical Centre. It is currently FDA-approved for Open-angle glaucoma, Ocular hypertension.

Latanoprost reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor, while timolol decreases aqueous humor production via beta-adrenergic receptor antagonism.

Latanoprost reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor, while timolol decreases aqueous humor production via beta-adrenergic blockade. Used for Open-angle glaucoma, Ocular hypertension.

At a glance

Generic nameLatanoprost/Timolol
SponsorUniversiti Kebangsaan Malaysia Medical Centre
Drug classProstaglandin analog / Beta-blocker combination
TargetProstaglandin F receptor (FP receptor) / Beta-adrenergic receptors (β1, β2)
ModalitySmall molecule
Therapeutic areaOphthalmology
PhaseFDA-approved

Mechanism of action

Latanoprost is a prostaglandin F2α analog that binds to prostaglandin F receptors on the ciliary muscle, facilitating drainage of fluid from the eye through the unconventional uveoscleral pathway. Timolol is a non-selective beta-blocker that reduces aqueous humor secretion by the ciliary body. Together, these complementary mechanisms provide additive intraocular pressure reduction.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Latanoprost/Timolol

What is Latanoprost/Timolol?

Latanoprost/Timolol is a Prostaglandin analog / Beta-blocker combination drug developed by Universiti Kebangsaan Malaysia Medical Centre, indicated for Open-angle glaucoma, Ocular hypertension.

How does Latanoprost/Timolol work?

Latanoprost reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor, while timolol decreases aqueous humor production via beta-adrenergic receptor antagonism.

What is Latanoprost/Timolol used for?

Latanoprost/Timolol is indicated for Open-angle glaucoma, Ocular hypertension.

Who makes Latanoprost/Timolol?

Latanoprost/Timolol is developed and marketed by Universiti Kebangsaan Malaysia Medical Centre (see full Universiti Kebangsaan Malaysia Medical Centre pipeline at /company/universiti-kebangsaan-malaysia-medical-centre).

What drug class is Latanoprost/Timolol in?

Latanoprost/Timolol belongs to the Prostaglandin analog / Beta-blocker combination class. See all Prostaglandin analog / Beta-blocker combination drugs at /class/prostaglandin-analog-beta-blocker-combination.

What development phase is Latanoprost/Timolol in?

Latanoprost/Timolol is FDA-approved (marketed).

What are the side effects of Latanoprost/Timolol?

Common side effects of Latanoprost/Timolol include Conjunctival hyperemia, Iris pigmentation increase, Eyelash growth (hypertrichosis), Eye irritation/discomfort, Headache, Bradycardia.

What does Latanoprost/Timolol target?

Latanoprost/Timolol targets Prostaglandin F receptor (FP receptor) / Beta-adrenergic receptors (β1, β2) and is a Prostaglandin analog / Beta-blocker combination.

Related